Company Appili Therapeutics Inc.

Equities

APLI

CA03783R1073

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Toronto S.E. Other stock markets 15:45:00 26/04/2024 BST			5-day change	1st Jan Change
0.04 ^CAD	0.00%		0.00%	+14.29%

04-02	Appili Therapeutics To be Acquired by Aditxt, Inc.	MT
04-02	Adivir, Inc. entered into a definitive agreement to acquire Appili Therapeutics Inc. for $6.7 million.	CI

Appili Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. The Companyâs anti-infective product development portfolio includes three programs, including ATI-1701, ATI-1801 and ATI-1501. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin that affects hundreds of thousands of people around the world annually. The ATI-1501 is a taste-masked liquid oral suspension formulation of the antibiotic metronidazole.

Number of employees: 9

CAD in Million	2022	Weight	2023	Weight	Delta
Biopharmaceutical 100.0 %	1	100.0 %	0	100.0 %	-75.97%

CAD in Million	2022	Weight	2023	Weight	Delta
Canada 100.0 %	1	100.0 %	0	100.0 %	-75.97%

Managers	Title	Age	Since
Don Cilla CEO	Chief Executive Officer	63	31/10/20
Armand Balboni CHM	Chairman	57	30/09/18
Kenneth Howling DFI	Director of Finance/CFO	66	15/11/21
Carl Gelhaus CTO	Chief Tech/Sci/R&D Officer	-	-
Leona Saunders LAW	General Counsel	-	-
Myriam Triest PRN	Corporate Officer/Principal	-	-
Stéphane Paquette PRN	Corporate Officer/Principal	-	30/09/19
Gary Nabors PRN	Corporate Officer/Principal	-	02/04/23

Members of the board	Title	Age	Since
Juergen Froehlich BRD	Director/Board Member	68	26/01/20
Prakash Gowd BRD	Director/Board Member	60	11-12
Rochelle Stenzler BRD	Director/Board Member	70	01/02/21
Brian Bloom BRD	Director/Board Member	48	06/05/15
Theresa Matkovits BRD	Director/Board Member	56	30/09/18
Armand Balboni CHM	Chairman	57	30/09/18
Don Cilla CEO	Chief Executive Officer	63	31/10/20

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	121,266,120	121,191,120 ( 99.94 %)	0	99.94 %

Name	Equities	%	Valuation
Brian Bloom 11.84 %	14,358,611	11.84 %	344 607 $
Don Cilla 0.0618 %	75,000	0.0618 %	1 800 $
Juergen Froehlich 0.000000 %	0	0.000000 %	- $
Prakash Gowd 0.000000 %	0	0.000000 %	- $
Kenneth Howling 0.000000 %	0	0.000000 %	- $
Rochelle Stenzler 0.000000 %	0	0.000000 %	- $
Theresa Matkovits 0.000000 %	0	0.000000 %	- $
Armand Balboni 0.000000 %	0	0.000000 %	- $
Yoav Golan 0.000000 %	0	0.000000 %	- $

Appili Therapeutics, Inc.

1344 Summer Street Suite 21

B3H 0A8, Halifax

http://www.appilitherapeutics.com

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
APPILI THERAPEUTICS INC.	+14.29%	3.54M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs